If you are looking for a Half-Life Extension (HLE) partner who can provide you with the right technology to help develop your biotherapeutic drug then Novozymes is the ideal choice.
Our first generation albumin-based technology has been proven and our “new and improved” platform offers you even longer half-life combined with a flexible approach and patent life to at least 2030.
We offer albumin-based HLE by genetic fusion (Albufuse® Flex) or chemical conjugation (Recombumin® Flex). Our tunable technology can extend half-life from “days to weeks”.
Novozymes‘ experienced specialists support you with the right technical and regulatory
information to make your product development and approval processes easier.
Albumin’s proven safety and regulatory profile, and its long history of therapeutic use, makes it an ideal choice for drug delivery. Variants have been designed with altered binding affinities to its receptor, making it possible to modulate its serum half-life.
Already demonstrated in the fields of diabetes, hemophilia and neutropenia, you too can reduce your drug dosing frequency from days to weeks and improve healthcare costs through using Novozymes’ recent advancements in albumin technology.
Designed by nature. Improved by Novozymes.